Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Established in 2006 and headquartered in Castelnau-le-Lez, France, NFL Biosciences S.A. is a biotechnology enterprise dedicated to pioneering natural remedies for addiction cessation, particularly for individuals seeking to quit smoking. Their most advanced therapeutic candidate, NFL-101, derived from tobacco, is currently progressing through Phase III clinical trials specifically designed to combat smoking addiction. Additionally, the company's research pipeline features NFL-201, an extract blending cannabis and tobacco, and NFL-301, a botanical formulation rooted in traditional Chinese medicine, both of which are undergoing preclinical assessment.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.